Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environment

‘Obesity Drug Markets in the US and EU: Analysis of product pipelines and competitive environment’ explores the dynamics and drivers of the market for current and emerging obesity treatments. This report evaluates the performances and attributes of currently marketed products and highlights the most effective strategies for securing future success in this therapeutic area.

The potential of leading obesity drug candidates is assessed and over 100 compounds are identified across pre-clinical, Phase I, Phase II and Phase III development. Forecasts of future sales are also provided, based upon trends in obesity drug usage, projected prevalence rates and the approval potential of emerging products. Explore the latest trends and innovations in obesity treatments, assess the performances of currently marketed medications and evaluate the potential of leading pipeline candidates with this report.

Read more...

• PharmaBrand (03/03/2010)
• Rheumatoid Arthritis (26/02/2010)
• Rheumatoid Arthritis (26/02/2010)

• Valuing Pharmaceutical Innovation (14/10/2008)
• The Anti-Infectives Market Outlook to 2013 (14/10/2008)
• Respiratory Disorders (14/10/2008)
• Monoclonal Antibodies Report (14/10/2008)
• EU Pharmaceutical Forum (11/10/2008)
• Neuropathic Pain (10/10/2008)
• Non-hormonal Treatments for Menopausal Symptoms (10/10/2008)
• Rx-to-OTC Strategies (10/10/2008)
• Asthma (10/10/2008)

---